Relmada Therapeutics (RLMD) Tops Q4 EPS by 5c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.28), $0.05 better than the analyst estimate of ($1.33).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Thor Industries names new leadership for North American RV operations
• Frequency Electronics (FEIM) Tops Q1 EPS by 12c